Clinical Trials Directory

Trials / Completed

CompletedNCT04763005

Hypertension and Retinal Microvascular Dysfunction

Hypertension and Retinal Microvascular Dysfunction: A Cross-sectional and Randomized Controlled Exercise Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
85 (actual)
Sponsor
University of Basel · Academic / Other
Sex
All
Age
40 Years – 70 Years
Healthy volunteers
Accepted

Summary

Hypertension is a worldwide health care burden that affects the structure and function of the macro- and microcirculation. Non-invasive vascular biomarkers are essential to timely diagnose end organ damage to improve cardiovascular (CV) risk stratification and medical decision making. The "Hypertension and retinal microvascular dysfunction" (HyperVasc) trial will investigate macro- and microvascular impairments in hypertensive patients and healthy controls to investigate hypertension-induced end organ damage by using gold-standard methods as well as newly developed and unique retinal microvascular biomarkers. Additionally, this trial will investigate the reversible effects of an eight weeks supervised and walking based high-intensity exercise intervention on blood pressure as well as macro- and microvascular health, compared to a control group with standard physical activity recommendations. Secondary outcomes will be cardiorespiratory fitness, physical activity, microalbuminuria, hypertensive retinopathy, and classical cardiovascular risk marker. The results of the HyperVasc trial will improve the understanding of hypertension-induced vascular impairments and will push the development of non-invasive vascular biomarker to screen end organ damage in general CV risk stratification.

Conditions

Interventions

TypeNameDescription
BEHAVIORALHIIT exercise interventionThe exercise intervention will be eight weeks of high-intensity interval training (HIIT) started by one warm-up week with an intensity of 75% maximum heart rate (HRmax). In the following seven weeks, the participants will perform a HIIT based on the following protocol and with a total duration of 45 minutes per session: warm-up for 10 minutes at 60-70% HRmax followed by a high-intensity interval consisting of 4x4 minutes at 80-90% HRmax with 3 minutes of active recovery at 60-70% HRmax and a 10 minutes cool-down at 60-70% HRmax. HR will be monitored during training by Polar® H7 heart rate sensors combined with Polar® M400 watches.
BEHAVIORALPhysical activity recommendationsThe control group will get physical activity recommendations based on actual guidelines from the European Association of Preventive Cardiology.

Timeline

Start date
2021-02-12
Primary completion
2022-05-01
Completion
2022-05-20
First posted
2021-02-21
Last updated
2022-06-03

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT04763005. Inclusion in this directory is not an endorsement.